The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Management of AEs from amivantamab and lazertinib for EGFR-m NSCLC
Shirish Gadgeel, MD, Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI, provides an overview of strategies to manage adverse events (AEs) related to amivantamab and lazertinib patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) may experience. Skin-related AEs are commonly reported, especially on the scalp, and prophylactics such as moisturizers and antibiotics are recommended. The COCOON trial (NCT06120140) is currently evaluating enhanced measures to combat dermatologic AEs. Infusion reactions may also occur in patients, and subcutaneous administration has shown to lower rates of such events. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
